Cardiology

Editorial: Cardiopulmonary Resuscitation after Hospital Admission with Covid-19 – The BMJ

“This pandemic has changed the risk-benefit balance for CPR: from “there is no harm in trying” to “there is little benefit to the patient, and potentially significant harm to staff.””

 


COVID-19 Pandemic and Cardiac Imaging

6 Apr, 2020 | 01:35h | UTC

COVID-19: Updates for Cardiologists

6 Apr, 2020 | 00:44h | UTC

Podcasts:

Guidelines:

“…among patients with COVID-19 infection, clinicians are advised to only measure troponin if the diagnosis of acute MI is being considered on clinical grounds and an abnormal troponin should not be considered evidence for an acute MI without corroborating evidence.”

Reviews:

Selected Articles:

COVID-19 Cardiology: This page will be updated as often as necessary and will be fixed in the right column on our homepage.

 


FDA Approves Label Changes to SGLT2 Inhibitors Regarding Temporary Discontinuation of Medication Before Scheduled Surgery – U.S. Food & Drug Administration (free)

Commentary: FDA advises stopping SGLT2 inhibitor treatment prior to surgery – The Hospitalist (free)

“- Canagliflozin, dapagliflozin, and empagliflozin should each be discontinued at least three days before scheduled surgery.

Ertugliflozin should be discontinued at least four days before scheduled surgery.

– Blood glucose levels should be carefully monitored after discontinuation of the SGLT2 inhibitor and appropriately managed before surgery.”

 


Association Between Renin-Angiotensin System Blockade Discontinuation and All-Cause Mortality Among Persons With Low Estimated Glomerular Filtration Rate – JAMA Internal Medicine (free for a limited period)

Editorial: Continuation of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the Face of Kidney Disease Progression—Safe and Possibly Life Saving (free for a limited period)

 

Related Commentary on Twitter

 


Blood pressure in frail older adults: associations with cardiovascular outcomes and all-cause mortality – Age and Ageing (free)

Commentary: Expert reaction to study looking at low blood pressure and mortality in older adults – Science Media Centre (free)

 

Related Commentary on Twitter

 


Effect of dose and duration of reduction in dietary sodium on blood pressure levels: systematic review and meta-analysis of randomised trials – The BMJ (free)

Commentaries: Further evidence adds weight to call for urgent action on salt targets – George Institute for Global Health (free) AND Cutting salt likely to prevent future heart disease, even if you’re not at risk now – CNN (free)

 

Related Commentary on Twitter

 


Evaluation of a Common Prescribing Cascade of Calcium Channel Blockers and Diuretics in Older Adults With Hypertension – JAMA Internal Medicine (free for a limited period)

Commentary: Antihypertensive Prescribing Cascades as High-Priority Targets for Deprescribing – JAMA Internal Medicine (free for a limited period)

 

Related Commentary on Twitter

 


Effects of Percutaneous Coronary Intervention on Death and Myocardial Infarction Stratified by Stable and Unstable Coronary Artery Disease: A Meta-Analysis of Randomized Controlled Trials – Circulation: Cardiovascular Quality and Outcomes (free)

Editorial: The ISCHEMIA Trial Meets the Rashomon Effect: Lessons for Clinical Practice (free for a limited period)

 

Related Commentary on Twitter

 


Effect of salt substitution on community-wide blood pressure and hypertension incidence – Nature Medicine (free for a limited period)

Commentaries Before Publication at #ESCCongress: Community-based salt substitution programme lowers blood pressure – European Society of Cardiology (free) AND Community-Level Salt-Swapping Strategy Pays Dividends in Peru – TCTMD (free)

 

Related Commentary on Twitter

 


Association of Use of an Intravascular Microaxial Left Ventricular Assist Device vs Intra-aortic Balloon Pump With In-Hospital Mortality and Major Bleeding Among Patients With Acute Myocardial Infarction Complicated by Cardiogenic Shock – JAMA (free for a limited period)

Editorial: Microaxial Left Ventricular Assist Devices: In Search of an Appropriate Indication (free for a limited period)

Commentary: High-tech pump may increase risk of death and bleeding, study finds – Yale News (free)

 

Related Commentary on Twitter (Thread – Click for More)

 


Electrical versus pharmacological cardioversion for emergency department patients with acute atrial fibrillation (RAFF2): a partial factorial randomised trial – The Lancet (link to abstract – $ for full-text)

Summary: Electrical vs Chemical Cardioversion in ED Patients With Atrial Fibrillation (RAFF2) – EMOttawa (free)

Related Study: Randomized Trial: Early vs. Delayed Cardioversion in Recent-Onset Atrial Fibrillation – New England Journal of Medicine (free study and commentaries)

 

Related Commentary on Twitter

 


Global, regional, and national burden of congenital heart disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 – The Lancet Child & Adolescent Health (free)

Invited Commentary: Congenital heart disease: a global public health concern (free)

Related: Findings from the Global Burden of Disease Study 2017 – The Lancet / Institute for Health Metrics and Evaluation (free PDF)

 

Related Commentary on Twitter

 


Alcohol Abstinence in Drinkers with Atrial Fibrillation – New England Journal of Medicine (link to abstract – $ for full-text)

Commentaries: Cutting out alcohol may reduce atrial fibrillation episodes – Reuters (free) AND Atrial Fibrillation and Alcohol Abstinence – MedicalResearch.com (free) AND Alcohol Abstinence Linked to Lower Risk for Atrial Fibrillation Recurrence – NEJM Journal Watch (free)

 

Related Commentary on Twitter

 


Effect of a Strategy of Comprehensive Vasodilation vs Usual Care on Mortality and Heart Failure Rehospitalization Among Patients With Acute Heart Failure: The GALACTIC Randomized Clinical Trial – JAMA (link to abstract – $ for full-text)

Commentary: No Survival Gain From Aggressive Vasodilator Strategy in Acute HF: GALACTIC – Medscape (free registration required)

 

Related Commentary on Twitter

 


Irbesartan in Marfan syndrome (AIMS): a double-blind, placebo-controlled randomised trial – The Lancet (free)

Invited Commentary: Angiotensin-II receptor blockade in Marfan syndrome – The Lancet (free)

 

Related Commentary on Twitter